메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Festive Season Isolation: How Eczema Is Keeping Singaporeans From Gatherings

[ 메디채널 김갑성 기자 ] Medical Channel Asia's ongoing eczema survey reveals how chronic itch drives withdrawal, emotional strain, and missed celebrations during a period traditionally associated with connection and joy. SINGAPORE, Dec. 29, 2025 -- For many, the festive season is marked by reunions, shared meals and long-awaited gatherings. For Mr Li, however, it often comes with apprehension. Festive periods tend to disrupt the routines that help him keep eczema and chronic itch under control. What is meant to be a time of celebration can quickly become overwhelming when the skin sta
- 김갑성 기자
- 2025-12-29 08:30
CARsgen Submits Dual IND Applications for Allogeneic BCMA CAR-T Product CT0596

SHANGHAI, Dec. 29, 2025 -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submitted two separate Investigational New Drug (IND) applications to the National Medical Products Administration (NMPA) for its allogeneic BCMA-targeted CAR-T cell therapy product, CT0596. The applications seek to initiate two corresponding Phase Ib/Ⅱ clinical trials for the treatment of relapsed/refractory multiple myeloma (R/R MM) and primary plasma cell leukemia (pPCL), respectively. CT0
- 김갑성 기자
- 2025-12-29 08:10
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly

- Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment - Accelerating R&D on core technologies, including expansion of indications for the Grabody platform SEOUL, South Korea, Dec. 26, 2025 -- ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity investment from Eli Lilly and Company ("Lilly&q
- 김갑성 기자
- 2025-12-26 12:55
Arspura Showcases a New Standard for Healthy Kitchen Living at CES 2026

LOS ANGELES, Dec. 26, 2025 -- From January 6–9, 2026, visitors can experience Arspura's next-generation range hoods at LVCC - South Hall 1- Booth 30725, where the brand will demonstrate how cleaner kitchen air can make everyday cooking more comfortable and confidence-building—especially for households that are more sensitive to fumes, odors, and lingering particles. For air-quality-conscious users, including people prone to nasal sensitivity, Arspura will highlight how thoughtful ventilation can help keep the cooking space feeling fresher and easier to enjoy. Cooking fumes and
- 김갑성 기자
- 2025-12-26 01:30
Life-Space TrioBiotic Series Lands in Southeast Asia, Revolutionizing Gut Health with Triple-Action Formula

KUALA LUMPUR, Malaysia, Dec. 25, 2025 -- A significant shift is underway in the regional health and wellness landscape as the innovative Life-Space TrioBiotic supplement series officially enters the Southeast Asian market. The launch introduces a cutting-edge "three-in-one" approach to gut health, combining prebiotics, probiotics, and postbiotics in a single daily dose. The world of health and wellness has been fundamentally transformed by the pivotal role of Probiotics in supporting gut health and overall well-being. Over the past decade, we have witnessed an explosive surge
- 김갑성 기자
- 2025-12-25 22:08
China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval

TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment of patients with stage IIB-III resectable microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) colon cancer. The TABOSUN® and TYVYT® combination therapy significantly improved pathological complete response (pCR) rates and enabled most patients to avoid the burden of postoperative adjuvant chemotherapy. This therapy is the first and only dual-IO regimen approved globally for neoadjuvant treatment of colon cancer[i], filli
- 김갑성 기자
- 2025-12-25 16:45
Life-space's Patented Strain LPB27 Featured in Nature Supplement, Highlighting World-Class R&D Strength

KUALA LUMPUR, Malaysia, Dec. 25, 2025 -- The Nature supplement highlights research exploring the potential of LPB27 and Bifidobacterium breve 207-1 in supporting digestive and metabolic health. Both strains have already been successfully integrated into multiple Life-space products and are highly favored by consumers globally. The inclusion of Life-space's proprietary strains in a Nature publication underscores the brand's robust scientific capabilities. Currently, the Life-space Global Microbiome Center manages an end-to-end research ecosystem encompassing strain isolation, genome seq
- 김갑성 기자
- 2025-12-25 10:14
Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies

Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management (CBL-0201WR Phase 2). The study will evaluate CBL-514 in combination with Zepbound® (Eli Lilly) in subjects with obesity or overweight. Efficacy endpoints include changes in abdominal subcutaneous fat volume (measured by MRI) and changes in body weight. The study design incorporates a long-term follow-up period after discontinuation of tirzepatide, focusing on key parameters relevant t
- 김갑성 기자
- 2025-12-25 10:05
Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026

SYDNEY, Dec. 24, 2025 -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the acceptance of an abstract on the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT), led by Prof Louise Emmett at St Vincent's Hospital Sydney, for oral presentation at the upcoming European Association of Urology (EAU) Congress 2026, Europe's biggest urological conference, to be held 13-16 Mar
- 김갑성 기자
- 2025-12-24 22:02
Mabwell Receives IND Clearance for Novel Anti-ST2 Monoclonal Antibody 9MW1911 to Initiate Phase IIa Study

SHANGHAI, Dec. 24, 2025 -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance from the U.S. Food and Drug Administration (FDA) for its self-developed anti-ST2 monoclonal antibody (R&D code: 9MW1911) to initiate a Phase IIa clinical study in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). As the first domestic anti-ST2 monoclonal antibody candidate to enter clinical trials, 9MW1911 binds to the ST2 receptor with high affinity to block the IL-33/ST2 sig
- 김갑성 기자
- 2025-12-24 22:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2026-01-01_THU

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 01일 16시 00분